Janux Therapeutics, Inc. — Q2 2022 Form 10-Q
Business context and reporting period
Quarter and six months ended June 30, 2022. Janux is a clinical-stage biopharmaceutical company developing cancer immunotherapies using its TRACTr and TRACIr platforms. It has no approved products and has generated no product-sales revenue; reported revenue is from its Merck research collaboration.
Financial performance and liquidity
Amounts below are in millions, except per-share data.
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Collaboration revenue | $2.4 | $0.5 | $4.0 | $0.9 |
| Research and development | $14.1 | $4.7 | $24.3 | $6.7 |
| General and administrative | $5.5 | $2.0 | $10.5 | $2.7 |
| Operating loss | $(17.3) | $(6.3) | $(30.8) | $(8.5) |
| Net loss | $(16.9) | $(6.2) | $(30.3) | $(8.5) |
| Net loss per share, basic and diluted | $(0.41) | $(0.62) | $(0.73) | $(1.52) |
Six-month operating cash use was $17.6 million, compared with $0.6 million in 2021. Investing activities provided $40.1 million, mainly from net maturities of short-term investments; financing provided $0.3 million. Cash, cash equivalents and short-term investments totaled $354.3 million at June 30, 2022; a further $0.8 million was restricted cash, bringing cash, cash equivalents and restricted cash to $59.2 million. Management said available cash and short-term investments should fund operations for at least 12 months after the filing, but not through regulatory approval and commercialization.
Total assets were $385.4 million and stockholders’ equity was $343.8 million. The filing reports no borrowings or financial debt. Operating lease liabilities were $23.4 million, including $0.1 million current; the long-term Torrey Plaza lease carries approximately $37.8 million in undiscounted minimum payments before incentives and imputed interest. No meaningful operating margin is presented for this development-stage company.
Material changes versus the prior comparable period
- Six-month net loss widened to $30.3 million from $8.5 million, primarily as research and development and G&A spending increased with expanded programs, personnel, facilities and public-company costs.
- R&D increased $17.6 million year over year for the six months, including higher preclinical program spending, personnel and stock-based compensation. G&A increased $7.8 million, largely reflecting stock-based compensation and public-company expenses.
- Collaboration revenue increased $3.1 million for the six months, reflecting more FTE research effort under the Merck agreement, including work following Merck’s selection of a second target in May 2022.
- Accumulated deficit reached $77.7 million. Six-month stock-based compensation expense was $8.4 million, versus $1.4 million in 2021.
- Available-for-sale investments had $1.9 million of gross unrealized losses at June 30, 2022, principally attributed by the company to interest-rate movements and economic conditions; no credit-loss allowance was recorded.
Outlook, commentary, risks and unusual items
- FDA clearance of the JANX007 investigational new drug application occurred in Q2 2022. Management expected to submit an IND for JANX008 in the second half of 2022, and for TROP2-TRACTr and the PD-L1xCD28 TRACIr candidate in 2023. These are forward-looking expectations, not guaranteed outcomes.
- Janux expects substantial operating losses and higher R&D and G&A costs for the foreseeable future, and says additional financing will be needed to develop and commercialize its candidates. Future financing may dilute shareholders or require granting rights to programs or technology.
- The Merck agreement provides research funding and potential development/regulatory milestones of up to $142.5 million per target, commercial milestones of up to $350 million per licensed product, and tiered royalties. These contingent amounts are excluded from recognized transaction price because significant revenue reversal was considered probable; Merck may terminate at its discretion.
- Principal risks include early-stage clinical uncertainty, potential T-cell engager safety issues including cytokine release syndrome and healthy-tissue toxicity, reliance on third-party manufacturers and research providers, financing needs, intellectual-property challenges, and possible COVID-19 or market disruptions. The company reported no material operational disruption from COVID-19 to date.
- The company had no material legal proceedings. Disclosure controls and procedures were assessed as effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Clinical progress and timing for JANX007, including whether the planned trial proceeds as expected, and subsequent IND timing for JANX008, TROP2-TRACTr and TRACIr.
- Cash burn, investment liquidity and management’s runway assumptions, especially as clinical-stage costs increase; the stated runway is at least 12 months, not through product approval.
- Merck research activity, remaining deferred revenue ($10.7 million at June 30, 2022), and the timing and conditions for any future milestone or royalty payments.
- Progress against the approximately $38 million Torrey Plaza lease commitment and the company’s other operating and manufacturing obligations.
- Clinical safety and efficacy evidence, manufacturing capacity, and the ability to raise capital without materially diluting shareholders.